IPO registrations (S-1, F-1) · Registrants
Seagen Inc.
- SEC CIK
- 1060736 · filings on EDGAR ↗
- Name on the registration
- SEATTLE GENETICS INC /WA
- Former names
- SEATTLE GENETICS INC /WA (2000–2020)
- Registration
- Form S-1, first filed 2000-11-20, last 2001-03-06; 1 initial registration, 5 amendments
- Outcome
- Final prospectus filed 2001-03-07
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- WA
- Business address
- 21823 30TH DRIVE SE, SUITE, Bothell, WA 98021
- EIN
- 91-1874389
- EDGAR entity type
- operating
- Insiders and CEO pay
- Seagen Inc. on the corporate pages
Offering terms
- Proposed price range
- $8.00–$10.00 per share (S-1/A filed 2001-03-06)
- Final price
- $7.00 per share, below the range (424B4 filed 2001-03-07, an initial public offering)
- Shares sold
- 7,000,000
- Gross proceeds
- $49,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol SGEN
- Lead underwriters
- J.P. Morgan (2,551,429 shares); CIBC World Markets (2,232,500 shares); BofA Securities (1,594,643 shares)
- Syndicate
- Initial Public; Seattle Genetics; A.G. Edwards (167,857); Ragen MacKenzie Incorporated (167,857)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: SEAGEN INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: Seagen Inc. Fuzzy (name and state)
- Business registration: Seagen Inc. Fuzzy (name and state)
- Business registration: Seagen Inc. Fuzzy (name and state)
- Business registration: Seagen Inc. Fuzzy (name and state)
- Business registration: SEAGEN INC. Fuzzy (name and state)
- Business registration: SEAGEN INC. Fuzzy (name and state)
- Business registration: SEAGEN INC. Fuzzy (name and state)
- Business registration: SEAGEN INC. Fuzzy (name and state)
- Form 5500 plan sponsor: SEAGEN INC. EXACT (EIN (EXACT))
- Federal award recipient: SEAGEN INC Fuzzy (name and state)
- SEC filer: Seagen Inc. EXACT (CIK (EXACT))
- Person page: David R Epstein Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
Filings 8
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2000-11-20 | S-1 | S-1 (registration) | SEATTLE GENETICS INC /WA | 0000912057-00-050883 ↗ |
| 2000-12-05 | S-1/A | S-1/A (amendment) | SEATTLE GENETICS INC /WA | 0000912057-00-052268 ↗ |
| 2001-01-04 | S-1/A | S-1/A (amendment) | SEATTLE GENETICS INC /WA | 0000912057-01-000247 ↗ |
| 2001-02-08 | S-1/A | S-1/A (amendment) | SEATTLE GENETICS INC /WA | 0000912057-01-004254 ↗ |
| 2001-02-23 | S-1/A | S-1/A (amendment) | SEATTLE GENETICS INC /WA | 0000912057-01-006533 ↗ |
| 2001-03-06 | S-1/A | S-1/A (amendment) | SEATTLE GENETICS INC /WA | 0000912057-01-007273 ↗ |
| 2001-03-07 | 424B4 | 424B4 (final prospectus) | SEATTLE GENETICS INC /WA | 0000912057-01-502760 ↗ |
| 2001-03-08 | 424B4 | 424B4 (final prospectus) | SEATTLE GENETICS INC /WA | 0000912057-01-007391 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2001-03-06 | S-1/A | registration statement | $8.00–$10.00 | 7,000,000 | - | Nasdaq SGEN | 5 | primary document; range, price table, shares headline, proceeds computed, price outside the range dropped, cover names 5 | document ↗ | |
| 2001-03-07 | 424B4 | final prospectus | $7.00 | 7,000,000 | $49,000,000 | Nasdaq SGEN | 7 | primary document; price sentence, shares headline, proceeds computed, underwriting table 5, cover names 5 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| DOBMEIER ERIC | Officer | Chief Business Officer; Chief Operating Officer; Sr. VP, Corporate Development | 69 | 2006–2017 | |
| ROSENBERG MORRIS | Officer | EVP, Development; EVP, Process Sciences; Sr. VP, Development; SVP, Development | 28 | 2006–2012 | |
| SIEGALL CLAY B | Director,Officer | President and CEO; President & CEO; See Remarks | 174 | 2006–2022 | |
| SIMPSON TODD E | Officer | Chief Financial Officer; See Remarks | 74 | 2006–2023 | |
| GRYSKA DAVID W | Director | 49 | 2006–2023 | ||
| Hoth Daniel Floyd JR | Director | 7 | 2006–2010 | ||
| AKKARAJU SRINIVAS | Director | 40 | 2006–2020 | ||
| JP MORGAN PARTNERS BHCA LP | TenPercentOwner | 12 | 2006–2008 | ||
| J P MORGAN PARTNERS GLOBAL INVESTORS A LP | TenPercentOwner | 8 | 2006–2008 | ||
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP | TenPercentOwner | 10 | 2006–2008 | ||
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP | Director; TenPercentOwner | 10 | 2006–2008 | ||
| JP MORGAN PARTNERS GLOBAL INVESTORS LP | Director; TenPercentOwner | 10 | 2006–2008 | ||
| JPMP CAPITAL CORP | TenPercentOwner | 10 | 2006–2008 | ||
| JPMP GLOBAL FUND BILL BARRETT SELLDOWN LP | TenPercentOwner | 2 | 2006 | ||
| JPMP GLOBAL INVESTORS L P | TenPercentOwner | 8 | 2006–2008 | ||
| JPMP MASTER FUND MANAGER L P | TenPercentOwner | 10 | 2006–2008 | ||
| Baker Biotech Capital II (GP), LLC | TenPercentOwner | 1 | 2006 | ||
| Baker Biotech Capital III (Z) (GP), LLC | TenPercentOwner | 1 | 2006 | ||
| Baker Biotech Capital II (Z) (GP), LLC | TenPercentOwner | 1 | 2006 | ||
| Baker Brothers Life Sciences Capital (GP), LLC | Director,TenPercentOwner | 30 | 2006–2012 | ||
| BAKER FELIX | Director; Director,Other; Director,TenPercentOwner | 160 | 2006–2023 | ||
| BAKER JULIAN | Director; Director,Other; Director,TenPercentOwner; TenPercentOwner | 153 | 2006–2023 | ||
| TrailSmith Pamela A | Officer | Chief Scientific Officer | 4 | 2006–2007 | |
| BERGER FRANKLIN M | Director | 22 | 2006–2014 | ||
| LIPPMAN MARC E | Director | 29 | 2006–2021 | ||
| SOUTHERN DOUGLAS | Director | 1 | 2006 | ||
| 14159 capital (GP), LLC | Director,TenPercentOwner | 26 | 2006–2011 | ||
| Baker Biotech Capital (GP), LLC | Director,TenPercentOwner | 22 | 2006–2012 | ||
| GALLEN JONATHAN | Other; TenPercentOwner | 10 | 2006–2007 | ||
| DELPHI BIOINVESTMENTS VI LP | TenPercentOwner | 1 | 2007 | ||
| DELPHI MANAGEMENT PARTNERS VI LLC | TenPercentOwner | 1 | 2007 | ||
| DELPHI VENTURES VI LP | TenPercentOwner | 1 | 2007 | ||
| JP MORGAN PARTNERS GLOBAL INVESTORS SELLDOWN II L P | TenPercentOwner | 6 | 2007–2008 | ||
| JP MORGAN PARTNERS GLOBAL INVESTORS SELLDOWN LLP | TenPercentOwner | 8 | 2007–2008 | ||
| Baker Bros. Capital (GP), LLC | Director,TenPercentOwner | 12 | 2007–2012 | ||
| Baker / Tisch Capital (GP), LLC | Director,TenPercentOwner | 7 | 2007–2012 | ||
| Reynolds Thomas C | Officer | Chief Medical Officer | 30 | 2007–2013 | |
| MCLAUGHLIN JOHN PETER | Director | 12 | 2007–2016 | ||
| WELCH DANIEL G | Director | 35 | 2007–2023 | ||
| H&Q Employee Venture Fund 2000, L.P. | TenPercentOwner | 4 | 2008 | ||
| H&Q Holdings, Inc. | TenPercentOwner | 4 | 2008 | ||
| HIMES VAUGHN B | Officer | Chief Technical Officer; EVP, Proc Svcs & Tech Ops; EVP, Technical Operations; EVP, Tech, Ops. & Proc. Sci.; EVP, Tech. Ops. & Proc. Sci.; See Remarks | 80 | 2009–2023 | |
| SEELEY BRUCE J. | Officer | EVP, Commerical | 4 | 2009–2011 | |
| BOERNER CHRISTOPHER S. | Officer | EVP, Commercial; Executive Vice President, Comm; SVP, Commercial | 8 | 2012–2014 | |
| Simonian Nancy A | Director | 16 | 2012–2023 | ||
| BAKER BROS ADVISORS LLC | Director,Other; Director,TenPercentOwner | 57 | 2012–2023 | ||
| FBB2 LLC | Director,TenPercentOwner | 1 | 2012 | ||
| 14159, L.P. | Director; Director,TenPercentOwner | 12 | 2013–2014 | ||
| 667, L.P. | Director; Director,Other; Director,TenPercentOwner | 57 | 2013–2023 | ||
| Baker Brothers Life Sciences LP | Director; Director,Other; Director,TenPercentOwner | 57 | 2013–2023 | ||
| Baker Bros. Advisors (GP) LLC | Director,Other; Director,TenPercentOwner | 56 | 2013–2023 | ||
| DRACHMAN JONATHAN G | Officer | CMO & EVP, R & D; See Remarks | 23 | 2013–2018 | |
| Orwin John A | Director | 13 | 2014–2023 | ||
| LIU JEAN I | Officer | Chief Legal Officer; EVP, Legal Affairs & GC; GC/EVP, Leg Afairs; GC/EVP, Leg Affairs; GC & EVP, Legal Affairs; GC/EVP, Legal Affairs; See Remarks | 53 | 2014–2023 | |
| FBB3 LLC | Director,TenPercentOwner | 1 | 2014 | ||
| Cline Darren S | Officer | EVP, Commercial; Executive Vice President; See Remarks; SVP, Commercial | 28 | 2015–2018 | |
| Seth Alpna | Director | 8 | 2018–2023 | ||
| DANSEY ROGER D | Officer | Chief Medical Officer; Interim CEO & CMO; President R&D & CMO; President, R&D & CMO; President, Research and Develo; See Remarks | 51 | 2018–2023 | |
| TAYLOR ROBIN G | Officer | Chief Commercial Officer | 4 | 2019 | |
| ROMP CHARLES R | Officer | EVP, Commercial; EVP, Commercial U.S. | 36 | 2020–2023 | |
| LOVE TED W | Director | 6 | 2020–2023 | ||
| Epstein David R | Director,Officer | CEO; Chief Executive Officer | 5 | 2022–2023 | person page Fuzzy |
| SWAIN SANDRA M | Director | 4 | 2022–2023 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | SEAGEN INC. | WA | State business registries | EIN (EXACT, as the state registration reports it) |
| Plan sponsor | SEAGEN INC. | WA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| SEC filer | Seagen Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Business registration | Seagen Inc. | State business registries | name and state | |
| Business registration | Seagen Inc. | State business registries | name and state | |
| Business registration | Seagen Inc. | State business registries | name and state | |
| Business registration | Seagen Inc. | State business registries | name and state | |
| Business registration | SEAGEN INC. | State business registries | name and state | |
| Business registration | SEAGEN INC. | State business registries | name and state | |
| Business registration | SEAGEN INC. | State business registries | name and state | |
| Business registration | SEAGEN INC. | State business registries | name and state | |
| Form 5500 plan sponsor | SEAGEN INC. | EIN (EXACT) | ||
| Federal award recipient | SEAGEN INC | Federal spending (USAspending) | name and state | |
| Person page | David R Epstein | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), WA first:
- CORIXA CORP WA
- ZYMOGENETICS INC WA
- NS Wind Down Co., Inc. WA
- Adaptive Biotechnologies Corp WA
- Juno Therapeutics, Inc. WA
- LeonaBio, Inc. WA
- Sana Biotechnology, Inc. WA
- Icosavax, Inc. WA
- Intrinsic Medicine, Inc. WA
- Aurion Biotech, Inc. WA
In other datasets, the same topic (Health) in WA:
- Nonprofit: ACUPUNCTURE RELIEF PROJECT (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health